Valuation: NEOVACS

Market Cap 4.09K 4.72K 3.87K 3.5K 6.57K 453K 6.62K 46.14K 17.75K 230K 17.73K 17.34K 732K P/E 2023 *
-
P/E 2024 -
Enterprise Value -201K -232K -190K -172K -323K -22.26M -325K -2.27M -873K -11.29M -872K -852K -35.99M EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99%
Yield 2023 *
-
Yield 2024 -
1 day-7.14%
1 week-23.53%
Current month-35.00%
1 month-61.88%
3 months-87.00%
6 months-97.40%
Current year-99.70%
1 week 0.25
Extreme 0.2524
0.46
1 month 0.25
Extreme 0.2524
0.89
Current year 0.25
Extreme 0.2524
267
1 year 0.25
Extreme 0.2524
4,200
3 years 0.25
Extreme 0.2524
32,000,000
5 years 0.25
Extreme 0.2524
351,920,000
10 years 0.25
Extreme 0.2524
351,920,000
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 01/10/2020
Chief Tech/Sci/R&D Officer 56 -
Director TitleAgeSince
Chairman 87 28/05/2003
Director/Board Member - 01/05/2020
Chairman - -
Date Insider Type Main position Quantity % Market Cap. Importance
27/02/21 Sell

Chief Executive Officer

2,505,144 1.3796%
23/02/21 Sell

Chief Executive Officer

6,391,053 3.5196%
23/02/21 Sell

Chief Executive Officer

1,108,947 0.6107%
Change 5-day change 1-year change 3-year change Capi.($)
-7.14%-23.53%-99.99%-100.00% 51.4K
+0.56%-3.38%-1.83%+8.00% 45.63B
-1.05%-2.13%+339.21%+538.89% 43.96B
+1.86%+4.76%+46.02%+28.27% 43.73B
-1.70%-0.99%+4.73%+73.72% 40.23B
-0.73%-4.72%+8.55%+37.89% 31.86B
-12.28%-13.79% - - 17.4B
+3.43%+4.49%+24.38%+120.52% 16.62B
+1.83%+3.20%+16.49%+32.73% 14.46B
+0.41%-2.32%+80.15%+31.93% 13.04B
Average -1.51%-4.06%+46.41%+85.77% 26.69B
Weighted average by Cap. -0.62%-2.09%+76.11%+129.68%

Financials

2023 2024
Net sales 533K 616K 504K 457K 857K 59.07M 863K 6.02M 2.32M 29.95M 2.31M 2.26M 95.52M 434K 501K 410K 371K 697K 48.06M 702K 4.9M 1.88M 24.37M 1.88M 1.84M 77.71M
Net income -8.74M -10.09M -8.27M -7.49M -14.05M -968M -14.15M -98.66M -37.96M -491M -37.92M -37.08M -1.57B -32.91M -38M -31.12M -28.18M -52.88M -3.65B -53.28M -371M -143M -1.85B -143M -140M -5.89B
Net Debt -237K -273K -224K -202K -380K -26.19M -383K -2.67M -1.03M -13.28M -1.03M -1M -42.35M -205K -237K -194K -176K -330K -22.71M -332K -2.31M -890K -11.52M -889K -870K -36.73M
Logo NEOVACS
NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).
Employees
16
Date Price Change Volume
15/09/26 0.2600 -7.14% 43,488
14/09/26 €0.2800 -6.67% 31,624
11/09/26 €0.3000 -6.25% 55,556
10/09/26 €0.3200 -8.60% 40,202
09/09/26 €0.3501 +2.97% 133,064
  1. Stock Market
  2. Stocks
  3. ALNEV Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!